首页/数据集/Supplemental Table 3 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer

Supplemental Table 3 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer

NIAID Data Ecosystem2026-05-02 收录

三阴性乳腺癌治疗

基因靶向治疗

数据链接：

https://figshare.com/articles/dataset/Supplemental_Table_3_from_Targeting_YES1_Disrupts_Mitotic_Fidelity_and_Potentiates_the_Response_to_Taxanes_in_Triple-Negative_Breast_Cancer/27603283 数据链接链接失效反馈

官方服务：

资源简介：

Overlapping DEGs sgYES1

应用场景：

创建时间：

2024-11-04

三阴性乳腺癌治疗

癌症免疫生物标志物

Summary This metadata record provides details of the data supporting the claims of the related manuscript: “Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer:

NIAID Data Ecosystem40

Genes regulated by Meis1 in murine Mll-AF9 leukemia cells. Mus musculus

白血病分子机制

基因靶向治疗

Leukemias with MLL-rearrangements are characterized by high expression of the homeo box gene MEIS1. In these studies, we knocked down Meis1 expression by shRNA lentivirus transduction in murine Mll-AF

NIAID Data Ecosystem20

Additional file 1 of Metformin sensitizes triple-negative breast cancer to histone deacetylase inhibitors by targeting FGFR4

三阴性乳腺癌治疗

药物协同作用

Supplementary Material 1: Fig. S1. Identification of Metformin-Sensitizing Genes via CRISPR-Cas9 Screening. A, The schematic diagram showed how CDTSL identified metformin-sensitizing genes and targete

DataCite Commons2025-03-17 更新20

DataSheet_1_VISTA Expression on Immune Cells Correlates With Favorable Prognosis in Patients With Triple-Negative Breast Cancer.pdf

三阴性乳腺癌治疗

预后标志物

V-domain Ig suppressor of T-cell activation (VISTA), a newly discovered negative immune checkpoint, is thought to be related to immunotherapy resistance and may become a new immune therapeutic target.

NIAID Data Ecosystem20

Data_Sheet_1_CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.docx

CAR-NKT细胞疗法

三阴性乳腺癌治疗

Antibody-derived chimeric antigen receptor (CAR) T cell therapy has achieved gratifying breakthrough in hematologic malignancies but has shown limited success in solid tumor immunotherapy. Monoclonal

NIAID Data Ecosystem20

Supplemental Table 3 from Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer

资源简介：

相关数据集